The estimated Net Worth of Azmi Nabulsi is at least $9.35 Milión dollars as of 15 July 2024. Dr Nabulsi owns over 10,901 units of Phathom Pharmaceuticals Inc stock worth over $4,495,873 and over the last 4 years he sold PHAT stock worth over $4,121,350. In addition, he makes $727,971 as Co-Founder & COO at Phathom Pharmaceuticals Inc.
Dr has made over 10 trades of the Phathom Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 10,901 units of PHAT stock worth $127,760 on 15 July 2024.
The largest trade he's ever made was buying 20,000 units of Phathom Pharmaceuticals Inc stock on 16 May 2022 worth over $163,200. On average, Dr trades about 7,120 units every 68 days since 2020. As of 15 July 2024 he still owns at least 240,421 units of Phathom Pharmaceuticals Inc stock.
You can see the complete history of Dr Nabulsi stock trades at the bottom of the page.
Dr. Azmi Nabulsi M.D., M.P.H. is the Co-Founder & COO at Phathom Pharmaceuticals Inc.
As the Co-Founder & COO of Phathom Pharmaceuticals Inc, the total compensation of Dr H at Phathom Pharmaceuticals Inc is $727,971. There are 2 executives at Phathom Pharmaceuticals Inc getting paid more, with Terrie Curran having the highest compensation of $3,459,100.
Dr H is 61, he's been the Co-Founder & COO of Phathom Pharmaceuticals Inc since . There are 2 older and 12 younger executives at Phathom Pharmaceuticals Inc. The oldest executive at Phathom Pharmaceuticals Inc is Tadataka Yamada, 75, who is the Independent Chairman of the Board.
Azmi's mailing address filed with the SEC is C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PAK, NJ, 07932.
Over the last 5 years, insiders at Phathom Pharmaceuticals Inc have traded over $112,538,769 worth of Phathom Pharmaceuticals Inc stock and bought 2,393,679 units worth $45,337,731 . The most active insiders traders include Capital Management, L.P.Ra ..., James N Topper a Pharmaceutical Co Ltd Takeda. On average, Phathom Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $2,226,815. The most recent stock trade was executed by Azmi Nabulsi on 15 July 2024, trading 10,901 units of PHAT stock currently worth $127,760.
phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.
Phathom Pharmaceuticals Inc executives and other stock owners filed with the SEC include: